NNBXF

Nanobiotix filed a routine 6-K with a press release disclosing its share count and voting rights…

This filing contains no new material information. The share count reflects recent capital raises (424B5 filings from May 2026). Monitor upcoming clinical catalysts (NANORAY-312 data) and any further…

Nanobiotix announced its inclusion in the Euronext Tech Leaders Index, a Euronext initiative to…

Index inclusion is a modest positive for visibility but does not alter the fundamental picture dominated by recent dilutive capital raises. Monitor for any increased institutional buying driven by…

Nanobiotix closed its global offering of 1,959,289 ordinary shares (€33.60 each), 225,373 ADSs…

With the offering closed, near-term dilution is now known. Watch for cash runway updates and clinical milestones for NBTXR3. The smaller-than-feared offering may relieve some bearish pressure, but…

Nanobiotix closed its global offering of 2,218,467 ordinary shares (including ADSs) and 345,099…

The capital raise removes near-term financing risk and extends runway to 2029, but the 14.92% discount and ~4.5% dilution are headwinds. Monitor upcoming NANORAY-312 Phase 3 data and Nanoprimer…